Lista de obras -

A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604)

artículo científico publicado en 2020

A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors

artículo científico

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer

artículo científico publicado en 2015

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

artículo científico publicado en 2018

ABO Genotype and the Risk of Gastric Cancer, Atrophic Gastritis, and Helicobacter pylori Infection

artículo científico publicado en 2011

Association between an 8q24 locus and the risk of colorectal cancer in Japanese

artículo científico publicado en 2009

Association between insulin-like growth factor-1 polymorphisms and stomach cancer risk in a Japanese population

Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese.

artículo científico publicado en 2009

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.

artículo científico publicado en 2016

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer

scientific article published on 17 July 2020

Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience.

artículo científico publicado en 2015

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehen

artículo científico publicado en 2017

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

scholarly article by Saori Mishima et al published 31 January 2019 in Journal for Immunotherapy of Cancer

Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.

artículo científico publicado en 2018

Clinicopathological features of PD-L1 expression with MMR, EBV status and cancer genome alterations in MGC

artículo científico publicado en 2017

Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients

artículo científico publicado en 2016

Development of circulating tumour DNA analysis for gastrointestinal cancers

scientific article published on 01 January 2020

Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205).

artículo científico publicado en 2016

Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy

artículo científico publicado el 1 de enero de 2010

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma

scientific article published on 01 November 2018

Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study

scientific article published on 12 November 2019

Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer

artículo científico publicado en 2010

Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib.

artículo científico publicado en 2016

Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: a retrospective study

artículo científico publicado en 2009

Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing

artículo científico publicado en 2019

Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer

artículo científico publicado en 2020

Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN

Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial

artículo científico publicado en 2019

Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407).

artículo científico publicado en 2017

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer

scientific article published on 09 January 2019

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients

artículo científico publicado en 2015

Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer

artículo científico publicado en 2016

Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution

artículo científico publicado en 2015

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

artículo científico publicado en 2017

The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced non-colorectal (Non-CRC) gastrointestinal cancer

The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan, GI-screen: Efficient identification of cancer genome alterations in advanced gastric cancer

The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer

The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-screen: Efficient identification of cancer genome alterations in advanced esophageal cancer

The Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan (SCRUM-Japan GI-SCREEN): Efficient identification of actionable cancer genome alterations in advanced colorectal and non-colorectal gastrointestinal cancer (GI Scree

The impact of molecular subtype on efficacy of chemotherapy and checkpoint inhibition in advanced gastric cancer

scientific article published on 10 March 2020

The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC)

Lista de obras de

A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604)

A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

ABO Genotype and the Risk of Gastric Cancer, Atrophic Gastritis, and Helicobacter pylori Infection

Association between an 8q24 locus and the risk of colorectal cancer in Japanese

Association between insulin-like growth factor-1 polymorphisms and stomach cancer risk in a Japanese population

Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese.

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer

Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience.

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehen

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.

Clinicopathological features of PD-L1 expression with MMR, EBV status and cancer genome alterations in MGC

Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients

Development of circulating tumour DNA analysis for gastrointestinal cancers

Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205).

Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma

Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study

Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer

Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib.

Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: a retrospective study

Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing

Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer

Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN

Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial

Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407).

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients

Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer

Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced non-colorectal (Non-CRC) gastrointestinal cancer

The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan, GI-screen: Efficient identification of cancer genome alterations in advanced gastric cancer

The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer

The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-screen: Efficient identification of cancer genome alterations in advanced esophageal cancer

The Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan (SCRUM-Japan GI-SCREEN): Efficient identification of actionable cancer genome alterations in advanced colorectal and non-colorectal gastrointestinal cancer (GI Scree

The impact of molecular subtype on efficacy of chemotherapy and checkpoint inhibition in advanced gastric cancer

The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC)